The Oncotest™ Enables Physicians

Improve Therapy Selection To Deliver the Right Drug to the Right Patient at the Right Time

Cancer of Unknown Origin

Oncologists have limited to no guidelines which therapy to choose. ​

We help them to avoid selecting ineffective drugs

Overcoming Recurring Ovarian Cancer

Gyn-onc surgeons can provide patient specimen during surgery. ​

Enabling you to avoid tumor resistance to your therapy​

Avoiding Glioblastoma Resistance

Neurosurgeons can send surgically removed tissue samples. ​

To leverage our tumor resistance assay, the SAGE Oncotest™.

For Late-Stage Patients

When the course of treatment has failed

Leverage the full NCCN guidelines to get best possible outcome.

To find the needle in the haystack.

“Advance beyond standard of care within standard of care.”

How the Oncotest™ Works:


We create live 3D microtumors of the patient’s biopsy in a day...


that retain the microenvironment and heterogeneity of the sample...


testing multiple drugs using our proprietary technologies...


to identify the most effective therapy in just one week.

Non-Response to extremely high in vitro dosages predict tumor resistance with high accuracy


  • Fresh patient sample shipped overnight
  • Cultured with extremely high drug doses over 5 days
  • Labelled with T3-Thymidine
  • Treatment effect are classified into 3 groups
    1. Resistant (red): 0-40%
    2. Intermediate (gray): 40-80%
    3. Potentially Sensitive (green): >80%


  • If the effect of an extremely high drug dosage was less than 40%, non of the patients responded to the therapy.
  • However, if the effect of an extremely high drug dosage was more than 80%, patients were most likely to respond, although it did not guarantee it.


  • An extreme drug resistance assay can reliably predict tumor resistance but prediction on tumor sensitivity is less reliable.
Scroll to Top

Learn how we helped 100 top brands gain success